SPRIM

What SPRIM does

SPRIM is a shared brand for two independent, founder-led companies that have been operating together in healthcare since 2001: SPRIM Global Investments (SGI), a Singapore-based investment firm that deploys strategic equity, debt, and royalty financing into clinical-stage biotechnology, medical devices, and pharma R&D services companies across 17 countries; and SPRIM Health Group (SHG), a European consulting and CRO group headquartered in Madrid that delivers integrated medical, marketing, and commercial consulting from offices in six European cities (Madrid, Milan, London, Paris, Lisbon, Berlin). SGI operates five investment vehicles across three sectors and holds 30+ portfolio companies, while SHG serves 30+ clients across pharma, medtech, digital health, consumer healthcare, and medical nutrition.

The group's underlying technology stack combines operator-led investment infrastructure (including the TrialCap platform for structured clinical-trial financing, launched in 2023) with clinical execution assets such as SPRIM PRO (300+ trials over 24 years) and the ObvioGo digital clinical trial platform (a sister-company asset featuring eConsent, eCOA, ePRO, EMR data integration, and Oracle EDC/CTMS connectivity, with ObvioGo 2.0 released in 2024). SGI's portfolio includes proprietary platforms such as mVECTATM for blood-brain-barrier delivery and HD-MAP for needle-free vaccine delivery.

SPRIM earns revenue through two distinct mechanics. SGI generates returns from capital appreciation, interest on debt facilities, and potential royalty streams across its portfolio, including a 2018-launched TKS1 life-sciences venture fund in partnership with Tikehau Capital (US$50M committed at initial closing). SHG generates fee-for-service revenue through integrated consulting engagements. The brand is privately held by co-founders Dr. Michael Shleifer, Ivan Jarry, and Olivier Shleifer, with no external parent company identified.

Name

SPRIM

Legal name

SPRIM

Website

https://sprim.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

251–500 employees

Short description

SPRIM is a shared brand for two independent founder-led healthcare firms operating since 2001: SPRIM Global Investments, a Singapore-based investor in clinical-stage biotech, medtech, and pharma R&D services; and SPRIM Health Group, a European consulting and CRO group serving pharma, medtech, and consumer healthcare clients.

Ownership category

akta.pro rank

Product category

Healthcare Investment & Consulting

NAICS

Portfolio Management and Investment Advice (523940), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Finance and Insurance (52)

SIC

Investment Advice (6282), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA)

akta.pro secondary industries

Pharmacovigilance, Risk Management & Medical Affairs CROs (HLAGAAAH), Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Healthcare consulting services
• Clinical research organization
• Life sciences investment
• Biotech venture capital
• Medical device financing

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices7 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Investment Returns (SGI): SGI generates returns through strategic equity investments, debt financing, and royalty financing deployed across clinical-stage biotech, medical devices, and pharma R&D services companies. Investment returns come from capital appreciation, interest payments on debt facilities, and potential royalty streams.
2. Consulting Services (SHG): SPRIM Health Group provides integrated medical, marketing, and commercial consulting services to healthcare industry clients across pharma, medtech, digital health, consumer healthcare and medical nutrition, generating fee-for-service revenue.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

SPRIM operates as a shared brand for two independent healthcare-focused companies. SPRIM Global Investments (SGI) deploys operator-led equity, debt, and royalty financing into clinical-stage biotech and late-stage medtech companies across 3 sectors with 30+ portfolio companies. SPRIM Health Group (SHG) provides integrated medical, marketing, and commercial consulting services to pharma, medtech, digital health, consumer healthcare, and medical nutrition clients across six European cities. The combined firm also operates the TrialCap platform for structured clinical trial financing and holds exposure to the ObvioGo digital clinical trial platform.

Product overview

SPRIM is a shared brand name for two specialized independent companies: SPRIM Global Investments (SGI), a Singapore-based investment firm deploying equity, debt, and royalty financing to clinical-stage biotech and medtech companies; and SPRIM Health Group (SHG), a European consulting and CRO group. SGI operates TrialCap, its structured clinical trial financing platform. SPRIM PRO, within SHG, provides clinical trial services with 24 years of experience across 300+ trials. The collaboration with ObvioHealth adds the ObvioGo digital trial platform for decentralized and hybrid trials. Together, the companies serve pharma, biotech, medtech, digital health, consumer healthcare, and medical nutrition sectors.

Differentiator

Problem solved

Functional benefit

Products and services

• SPRIM Global Investments (SGI)
• SPRIM Health Group (SHG)
• TrialCap
• SPRIM PRO
• ObvioGo

Named customers11 records

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Six partnerships are on record, tiered core and strategic.

• ObvioHealthcoreStrategic or Co-development Partner · 15 July 2025SPRIM PRO and ObvioHealth, sister companies within the SPRIM Group, expanded collaboration to offer fully integrated clinical trial solution. Partnership combines SPRIM PRO's 24 years of clinical experience across 300+ trials with ObvioHealth's ObvioGo platform for decentralized and hybrid trials. Designed to help trial sponsors accelerate study startup, improve participant engagement, and deliver regulatory-ready data.
• OraclecoreTechnology or IntegrationObvioGo platform is seamlessly integrated with Oracle's electronic data capture (EDC) and clinical trial management system (CTMS) software, providing automated data management, formatting, and data reporting capabilities.
• DedalusstrategicTechnology or IntegrationGroundbreaking partnership announced to unite real-world clinical trial data. Dedalus provides healthcare IT solutions and data integration capabilities.
• NovotechstrategicChannel Partner/ Reseller/ DistributorStrategic partnership expanding virtual clinical trials capabilities. Novotech is a CRO partner providing clinical development services.
• VCTC LimitedstrategicStrategic or Co-development PartnerSGI completed equity investment in VCTC, a UK-based specialist clinical trial site. VCTC provides virtual and decentralized clinical trial capabilities in the UK, offering high-quality, cost-effective solutions that increase patient access to clinical trials. Investment enables cross-portfolio synergies.
• 35 Countries NetworkstrategicOthersObvioHealth operates clinical trials across 35 countries with access to network of hospitals and research centers through partnerships like Guardant Health.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• TVM Capital Healthcare: Healthcare-focused growth and venture investor with operating expertise. Comparable to SGI in combining operating know-how with clinical-stage capital deployment across multiple vehicles.
• NovaQuest Capital Management: Specialist in structured financing for clinical development, including royalty and debt arrangements. Comparable to SGI's TrialCap platform and the structured-debt tranches SGI has deployed (e.g., Vaxxas $40M debt, Spexis convert).
• Science 37 (Medidata): Decentralized clinical trial orchestration platform now part of Medidata/Dassault. Comparable to ObvioGo as a DCT platform serving biotech and pharma sponsors with site and patient-facing technology.
• Sofinnova Partners: European-headquartered life sciences VC with deep biotech and medtech focus. Comparable to SGI as an early-stage healthcare specialist with operator-style portfolio support and clinical development orientation.
• Tikehau Capital: Alternative asset manager that co-launched TKS1 with SPRIM in 2018. Comparable as a fund co-sponsor and life sciences capital partner, with broader multi-asset capabilities.
• Medable: Decentralized and hybrid clinical trial technology platform. Comparable to ObvioHealth's ObvioGo offering within the SPRIM ecosystem as a DCT enablement competitor.

Broad incumbents

• OrbiMed Advisors: Healthcare-dedicated investment firm with substantially larger AUM and broader stage coverage. Comparable to SGI as a specialist life sciences investor, but at significantly greater scale across private equity, royalty, and public equity strategies.
• ZS Associates: Global healthcare-dedicated consulting firm serving pharma, biotech, and medtech clients. Comparable to SHG's medical/marketing/commercial consulting practice for life sciences companies.
• Syneos Health: Integrated CRO and commercial consulting provider. Comparable to SHG's combined clinical operations and commercial/marketing consulting model for pharma and biotech sponsors.
• ICON plc: Global CRO with extensive clinical operations and consulting capabilities. Comparable to SHG's CRO/consulting business but at vastly greater scale across geographies and service lines.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Instagraminstagram.com/sprimglobal

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments5 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SPRIM